Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans

NCT07852949 | Not Yet Recruiting DMC

• 2 other identifiers: 2026-1108NCI-2026-07264
• Study Type: interventional
• Target: 94
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to learn if a digital communication tool can improve how well patients with head and neck cancer and their caregivers understand the disease and treatment plan after their first consultation visit with the doctor/nurse practitioner.

Conditions

Head and Neck Cancer; Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• Safety and Adverse Events (AEs)

  Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

  Through study completion; an average of 1 year

Study Arms (1)

Patient/Caregiver: Use of MyCareGorithm

EXPERIMENTAL

Following use of the digital visual communication tool by the provider, patients and any accompanying caregivers will be asked to complete their surveys via REDCap. Providers will complete their survey immediately after the consultation with each participating patient, also via REDCap. Each survey requires approximately 5 minutes to complete. No follow-up surveys or repeat administrations are planned.

Other: Survey

Interventions

Survey OTHER

A 6-item structured questionnaire with Yes/No response options, followed by one open-ended free-text question.

Patient/Caregiver: Use of MyCareGorithm

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients
• Adults aged 18 to 100 years.
• Diagnosed with head and neck cancer (all histologies included).
• Receiving treatment for head and neck and prostate cancer at MDACC
• Able to speak and understand English
• Caregivers
• Adults (≥18 years old).
• Able to speak and understand English.
• Providers
• Doctors or nurse practitioners practicing in the field of radiation oncology and actively participating in initial consultations for patients with head and neck cancer and prostate cancer.
• Must complete the provider survey after the consultation.

You may not qualify if:

• Patients
• Individuals without a diagnosis of head and neck cancer or prostate cancer.
• Patients who do not speak English (since the digital tool is not translated).
• Caregivers
• Adults who are not caregivers of the eligible patient
• Caregivers who do not speak English (tool not translated).
• Providers
• Doctors or nurse practitioners not practicing in the field of radiation oncology and not part of the initial consultation process.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

UT MD Anderson

Houston, Texas, 77030, United States

Location

Related Links

• UT MD Anderson Website

MeSH Terms

Conditions

Head and Neck Neoplasms; Prostatic Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Steven J Frank, MD

  UT MD Anderson

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Steven J Frank, MD

CONTACT

(713) 563-3601; sjfrank@mdanderson.org

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DEVICE FEASIBILITY
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2026
• First Posted: October 1, 2026
• Study Start (Estimated): March 1, 2027
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2029
• Last Updated: October 1, 2026

Record last verified: 2026-09

Locations

US (1)